Acadia Pharmaceuticals (ACAD) Enterprise Value (2010 - 2026)

Acadia Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$851.5 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 24.92% year-over-year to -$851.5 million; the TTM figure through Mar 2026 stood at -$851.5 million (down 24.92% YoY), while the FY2025 annual figure was -$819.7 million, down 8.43% from the prior year.
• Enterprise Value was -$851.5 million for Q1 2026 at Acadia Pharmaceuticals, down from -$819.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$345.9 million in Q3 2023 to a low of -$851.5 million in Q1 2026.
• Historically, Enterprise Value has averaged -$562.0 million across 5 years, with a median of -$470.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value rose 22.81% in 2022, then tumbled 72.26% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$416.8 million in 2022, then decreased by 5.29% to -$438.9 million in 2023, then tumbled by 72.26% to -$756.0 million in 2024, then dropped by 8.43% to -$819.7 million in 2025, then slipped by 3.88% to -$851.5 million in 2026.
• The last three Enterprise Value figures came in at -$851.5 million (Q1 2026), -$819.7 million (Q4 2025), and -$847.0 million (Q3 2025), per Business Quant data.